Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Other Accumulated Expenses (2018 - 2019)

Cyclerion Therapeutics has reported Other Accumulated Expenses over the past 2 years, most recently at $5.6 million for Q1 2019.

  • For Q1 2019, Other Accumulated Expenses changed N/A year-over-year to $5.6 million; the TTM value through Mar 2019 reached $5.6 million, changed N/A, while the annual FY2018 figure was $9.8 million, N/A changed from the prior year.
  • Other Accumulated Expenses for Q1 2019 was $5.6 million at Cyclerion Therapeutics, down from $9.8 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $9.8 million in Q4 2018 and troughed at $5.6 million in Q1 2019.